Ascendis Pharma (ASND) issues 15,060 staff warrants at $254.57 strike price

Rhea-AI Filing Summary

Ascendis Pharma A/S granted new employee equity incentives through warrants. On August 11, 2026, the board approved an aggregate grant of 15,060 warrants to certain employees under Appendix 1a to the company’s Articles of Association, and amended the Articles to provide for these grants.

Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of US $254.57 per share, equal to the closing price on the grant date. Subject to earlier vesting upon specified exit events, 25% of the warrants will vest on the one-year anniversary of the grant date, and the remaining 75% will vest in 1/36th monthly installments thereafter, in each case subject to continued service. After this grant, warrants to subscribe for an additional 1,524,443 shares remain available for future grant under the Articles of Association.

Filing Explained

This filing adds a registration-document consequence: the company says the report is incorporated by reference into its listed Form S-8 and F-3 registration statements, while the disclosed transaction remains at the warrant-grant stage.

Key Figures

Warrants granted: 15,060 warrants Exercise price: US $254.57 per share Initial vesting portion: 25% +3 more

6 metrics

Warrants granted 15,060 warrants Aggregate warrants granted to certain employees on August 11, 2026

Exercise price US $254.57 per share Exercise price per warrant, equal to closing price on grant date

Initial vesting portion 25% Vests on the one-year anniversary of the grant date

Remainder vesting portion 75% Vests in 1/36th monthly installments after the first year

Warrants remaining for future grants 1,524,443 shares Additional shares available for future warrant grants under Articles of Association

Grant date August 11, 2026 Date on which the board approved the warrant grants

Key Terms

Form 6-K, warrants, Articles of Association, vesting, +1 more

5 terms

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

warrants financial

"the Company’s board of directors granted an aggregate of 15,060 warrants"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Articles of Association regulatory

"under the terms of Appendix 1a to the Company’s Articles of Association"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

vesting financial

"25% of the Warrants will vest on the one year anniversary of the date of grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exit events financial

"Subject to earlier vesting upon the occurrence of certain exit events"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/12/2026 - 05:16 PM Accepted by SEC EDGAR 08/12/2026 - 05:15 PM Learn about SEC filing dates

FAQ

What did Ascendis Pharma (ASND) announce regarding new warrants?

Ascendis Pharma granted 15,060 warrants to certain employees on August 11, 2026. Each warrant can be exercised for one ordinary share under the company’s Articles of Association, providing equity-based incentives tied to the company’s share price.

What is the exercise price of the new Ascendis Pharma (ASND) warrants?

The warrants have an exercise price of US $254.57 per share, equal to the closing price of Ascendis Pharma’s ordinary shares on the grant date. This price sets the cost at which employees may subscribe for future shares.

How do the Ascendis Pharma (ASND) employee warrants vest?

The warrants vest over time: 25% vests on the one-year anniversary of the grant, and the remaining 75% vests in 1/36th per month thereafter, subject to continued service and potential earlier vesting upon certain exit events.

How many additional Ascendis Pharma (ASND) warrants remain available for future grants?

After this grant, warrants to subscribe for an additional 1,524,443 shares remain available for future issuance. These future warrants may be granted by the board under the company’s Articles of Association framework.

Did Ascendis Pharma (ASND) change its Articles of Association for these warrants?

Yes. In connection with the grant of the 15,060 warrants, Ascendis Pharma amended its Articles of Association to provide for this grant, aligning the corporate governing documents with the new warrant issuance.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Warrant Grants

On August 11, 2026, the Company’s board of directors granted an aggregate of 15,060 warrants to certain employees of the Company (the “Warrants”) under the terms of Appendix 1a to the Company’s Articles of Association. In connection with the grant of these Warrants, the Company amended its Articles of Association to provide for the grant of these Warrants. Each Warrant confers the right to subscribe for one ordinary share of the Company and has an exercise price equal to US $254.57 per share, the closing price of the Company’s ordinary shares as reported on the date of grant. Subject to earlier vesting upon the occurrence of certain exit events, 25% of the Warrants will vest on the one year anniversary of the date of grant and the remaining 75% will vest at a rate of 1/36th per month from one year after the date of grant, subject to continued service.

After giving effect to the grant of the Warrants described above, warrants to subscribe for an additional 1,524,443 shares of the Company remain available for future grant by the Company’s board of directors pursuant to the Company’s Articles of Association. The foregoing description of the material terms of the Warrants is qualified in its entirety by reference to the Company’s Articles of Association, which is included as Exhibit 1.1 hereto and incorporated by reference herein.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: August 12, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 502.3 KB